Dulta, K. Et Al. 2021. Mucormycosis: A Double Threat to COVID-19 Patients. PHARMACOLOGYONLINE , vol.3 , 1663-1677.

Dulta, K., Kumar, K., KOŞARSOY AĞÇELİ, G., Chauhan, P. K., & Kumar, V., (2021). Mucormycosis: A Double Threat to COVID-19 Patients. PHARMACOLOGYONLINE , vol.3, 1663-1677.

Dulta, Kanika Et Al. "Mucormycosis: A Double Threat to COVID-19 Patients," PHARMACOLOGYONLINE , vol.3, 1663-1677, 2021

Dulta, Kanika Et Al. "Mucormycosis: A Double Threat to COVID-19 Patients." PHARMACOLOGYONLINE , vol.3, pp.1663-1677, 2021

Dulta, K. Et Al. (2021) . "Mucormycosis: A Double Threat to COVID-19 Patients." PHARMACOLOGYONLINE , vol.3, pp.1663-1677.

@article{article, author={Kanika Dulta Et Al. }, title={Mucormycosis: A Double Threat to COVID-19 Patients}, journal={PHARMACOLOGYONLINE}, year=2021, pages={1663-1677} }